NK-063

NK-063 is a preclinical-stage natural killer (NK) cell therapy candidate being developed by Shanghai NK Cell Technology (also known as NK CellTech). The therapy utilizes a proprietary engineered NK cell approach designated as NKR-NK+ (NK cell receptor-engineered NK cells), which involves modifying NK cells to express specific receptors intended to enhance their recognition and lysis of tumor cells. While the specific molecular targets and technical details of the NKR-NK+ modification remain undisclosed, the candidate is part of a broader pipeline of next-generation NK cell therapies aimed at treating various unspecified tumors. The developer, based in Shanghai, China, leverages extensive research experience in cellular immunotherapy to optimize the persistence and anti-tumor efficacy of these engineered cells.